A Phase 4 interventional study of loratadine and fexofenadine in Rhinitis, sponsored by Bayer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-11.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and
Fexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamber; those who demonstrate an adequate allergic response determined by the Major Symptom Complex (MSC) score will then receive drug.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
This study's enrollment of 255 is above the median of 80 across 187 interventional studies indexed under Rhinitis.
Browse Rhinitis studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
urine pregnancy test at Screening (Visit 1) and Visit 4 (prior to randomization) and agree to use (and/or have their partner use) 2 acceptable methods of beginning at the Screening visit and throughout the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
Drug: loratadine · Drug: placebo to fexofenadine
Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
Drug: fexofenadine · Drug: placebo to loratadine
Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
Drug: placebo to loratadine · Drug: placebo to fexofenadine
loratadine, one 10 mg tablet, orally
Also known as: SCH 029851
fexofenadine, one 180 mg tablet, orally
one tablet, orally
one tablet, orally
Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)
The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point
The individual symptom score for Runny Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point
The individual symptom score for Itchy Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point
The individual symptom score for Sneezing was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point
The individual symptom score for Water Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point
The individual symptom score for Itchy Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point
The individual symptom score for Nasal Congestion was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point
The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
Time frame: From time of sensitization (time 0) to end of visit (~8 hours)
| Milestone | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| Started | 85 | 85 | 85 |
| Completed | 85 | 85 | 85 |
| Not completed | 0 | 0 | 0 |
The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 180 minutes (n=85, n=85, n=85) | 7.4 ± 4.51 | 6.7 ± 4.86 | 8.5 ± 5.07 |
| 195 minutes (n=85, n=85, n=85) | 7.5 ± 4.84 | 6.7 ± 4.87 | 8.9 ± 5.31 |
| 210 minutes (n=85, n=85, n=85) | 7.3 ± 4.73 | 6.5 ± 4.87 | 8.7 ± 5.28 |
| 225 minutes (n=85, n=85, n=85) | 7.4 ± 4.63 | 6.5 ± 4.70 | 8.5 ± 5.36 |
| 240 minutes (n=84, n=85, n=85) | 7.4 ± 4.76 | 6.5 ± 4.43 | 8.3 ± 5.38 |
| 255 minutes (n=85, n=85, n=85) | 7.1 ± 4.78 | 6.3 ± 4.47 | 8.4 ± 5.51 |
| 270 minutes (n=85, n=85, n=85) | 7.0 ± 4.67 | 6.4 ± 4.50 | 8.4 ± 5.56 |
| 285 minutes (n=85, n=85, n=85) | 7.3 ± 4.52 | 6.9 ± 4.76 | 8.7 ± 5.76 |
| 300 minutes (n=84, n=85, n=85) | 7.1 ± 4.54 | 6.5 ± 4.65 | 8.4 ± 5.58 |
The individual symptom score for Runny Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes | 3.4 ± 0.77 | 3.2 ± 0.78 | 3.3 ± 0.89 |
| 15 minutes | 3.1 ± 0.85 | 3.0 ± 0.91 | 3.0 ± 1.09 |
| 30 minutes | 3.0 ± 0.95 | 2.9 ± 0.99 | 2.9 ± 1.14 |
| 45 minutes | 2.8 ± 0.99 | 2.6 ± 1.05 | 2.8 ± 1.15 |
| 60 minutes | 2.7 ± 1.06 | 2.3 ± 1.02 | 2.7 ± 1.20 |
| 75 minutes | 2.6 ± 1.06 | 2.2 ± 1.08 | 2.6 ± 1.20 |
| 90 minutes | 2.4 ± 1.04 | 2.1 ± 1.08 | 2.4 ± 1.28 |
| 105 minutes | 2.4 ± 1.10 | 2.1 ± 1.03 | 2.5 ± 1.16 |
| 120 minutes | 2.1 ± 1.07 | 2.0 ± 1.00 | 2.3 ± 1.18 |
| 135 minutes | 2.2 ± 1.12 | 2.0 ± 1.07 | 2.4 ± 1.19 |
| 150 minutes | 2.3 ± 1.10 | 2.0 ± 1.07 | 2.4 ± 1.20 |
| 165 minutes | 2.2 ± 1.07 | 1.8 ± 1.14 | 2.3 ± 1.18 |
| 180 minutes | 2.1 ± 1.20 | 1.9 ± 1.20 | 2.3 ± 1.17 |
| 195 minutes | 2.1 ± 1.27 | 1.9 ± 1.21 | 2.4 ± 1.20 |
| 210 minutes | 2.0 ± 1.23 | 1.8 ± 1.22 | 2.3 ± 1.24 |
| 225 minutes | 2.1 ± 1.22 | 1.8 ± 1.24 | 2.3 ± 1.19 |
| 240 minutes | 2.0 ± 1.23 | 1.8 ± 1.19 | 2.2 ± 1.20 |
| 255 minutes | 2.0 ± 1.30 | 1.7 ± 1.15 | 2.3 ± 1.28 |
| 270 minutes | 1.9 ± 1.30 | 1.8 ± 1.10 | 2.3 ± 1.35 |
| 285 minutes | 2.1 ± 1.24 | 1.9 ± 1.15 | 2.3 ± 1.31 |
| 300 minutes | 2.0 ± 1.26 | 1.8 ± 1.14 | 2.3 ± 1.28 |
| 315 minutes | 2.1 ± 1.25 | 1.8 ± 1.17 | 2.4 ± 1.30 |
| 330 minutes | 2.2 ± 1.26 | 1.8 ± 1.18 | 2.3 ± 1.31 |
| 345 minutes | 2.1 ± 1.27 | 1.8 ± 1.17 | 2.4 ± 1.32 |
| 360 minutes | 2.1 ± 1.29 | 1.9 ± 1.23 | 2.3 ± 1.33 |
The individual symptom score for Itchy Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes | 3.3 ± 0.74 | 3.3 ± 0.73 | 3.4 ± 0.77 |
| 15 minutes | 3.1 ± 0.84 | 3.2 ± 0.81 | 3.1 ± 0.93 |
| 30 minutes | 2.8 ± 0.97 | 2.8 ± 0.97 | 2.8 ± 0.99 |
| 45 minutes | 2.7 ± 1.02 | 2.6 ± 0.96 | 2.8 ± 1.04 |
| 60 minutes | 2.6 ± 1.09 | 2.4 ± 1.05 | 2.6 ± 1.07 |
| 75 minutes | 2.4 ± 1.16 | 2.3 ± 1.14 | 2.5 ± 1.19 |
| 90 minutes | 2.3 ± 1.10 | 2.1 ± 1.07 | 2.4 ± 1.17 |
| 105 minutes | 2.2 ± 1.08 | 2.1 ± 1.10 | 2.4 ± 1.10 |
| 120 minutes | 1.9 ± 1.14 | 1.8 ± 1.12 | 2.1 ± 1.20 |
| 135 minutes | 2.0 ± 1.12 | 1.8 ± 1.17 | 2.2 ± 1.22 |
| 150 minutes | 2.1 ± 1.06 | 1.8 ± 1.19 | 2.2 ± 1.18 |
| 165 minutes | 2.0 ± 1.09 | 1.7 ± 1.22 | 2.2 ± 1.14 |
| 180 minutes | 2.0 ± 1.16 | 1.8 ± 1.25 | 2.2 ± 1.12 |
| 195 minutes | 1.9 ± 1.23 | 1.7 ± 1.22 | 2.2 ± 1.20 |
| 210 minutes | 2.0 ± 1.25 | 1.7 ± 1.28 | 2.2 ± 1.20 |
| 225 minutes | 1.9 ± 1.18 | 1.7 ± 1.27 | 2.2 ± 1.25 |
| 240 minutes | 1.9 ± 1.14 | 1.7 ± 1.24 | 2.2 ± 1.24 |
| 255 minutes | 1.8 ± 1.24 | 1.7 ± 1.21 | 2.2 ± 1.30 |
| 270 minutes | 1.9 ± 1.18 | 1.7 ± 1.25 | 2.1 ± 1.31 |
| 285 minutes | 1.9 ± 1.17 | 1.8 ± 1.22 | 2.2 ± 1.29 |
| 300 minutes | 1.8 ± 1.19 | 1.8 ± 1.20 | 2.1 ± 1.32 |
| 315 minutes | 1.8 ± 1.26 | 1.8 ± 1.22 | 2.2 ± 1.38 |
| 330 minutes | 1.8 ± 1.16 | 1.7 ± 1.25 | 2.1 ± 1.31 |
| 345 minutes | 1.9 ± 1.23 | 1.7 ± 1.29 | 2.2 ± 1.36 |
| 360 minutes | 1.8 ± 1.22 | 1.8 ± 1.32 | 2.2 ± 1.38 |
The individual symptom score for Sneezing was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes (n=85, n=85, n=85) | 1.3 ± 1.37 | 1.2 ± 1.36 | 1.5 ± 1.40 |
| 15 minutes (n=85, n=85, n=85) | 1.2 ± 1.31 | 1.2 ± 1.39 | 1.3 ± 1.37 |
| 30 minutes (n=85, n=85, n=85) | 1.2 ± 1.34 | 1.1 ± 1.32 | 1.2 ± 1.38 |
| 45 minutes (n=85, n=85, n=85) | 1.0 ± 1.29 | 0.9 ± 1.22 | 1.3 ± 1.39 |
| 60 minutes (n=85, n=85, n=85) | 1.1 ± 1.21 | 0.7 ± 1.12 | 1.2 ± 1.36 |
| 75 minutes (n=85, n=85, n=85) | 1.0 ± 1.25 | 0.8 ± 1.16 | 1.1 ± 1.39 |
| 90 minutes (n=85, n=85, n=85) | 0.7 ± 1.12 | 0.6 ± 1.07 | 1.0 ± 1.37 |
| 105 minutes (n=85, n=85, n=85) | 0.8 ± 1.16 | 0.6 ± 1.07 | 1.1 ± 1.43 |
| 120 minutes (n=85, n=85, n=85) | 0.5 ± 0.88 | 0.5 ± 1.04 | 0.9 ± 1.28 |
| 135 minutes (n=85, n=85, n=85) | 0.8 ± 1.13 | 0.7 ± 1.20 | 1.2 ± 1.48 |
| 150 minutes (n=85, n=85, n=85) | 0.9 ± 1.22 | 0.6 ± 1.14 | 1.1 ± 1.32 |
| 165 minutes (n=85, n=85, n=85) | 0.8 ± 1.11 | 0.5 ± 1.03 | 0.9 ± 1.32 |
| 180 minutes (n=85, n=85, n=85) | 0.7 ± 1.08 | 0.6 ± 1.11 | 0.9 ± 1.30 |
| 195 minutes (n=85, n=85, n=85) | 0.8 ± 1.19 | 0.6 ± 1.09 | 1.0 ± 1.38 |
| 210 minutes (n=85, n=85, n=85) | 0.7 ± 1.07 | 0.5 ± 1.03 | 1.0 ± 1.31 |
| 225 minutes (n=85, n=85, n=85) | 0.7 ± 1.04 | 0.6 ± 0.93 | 0.9 ± 1.33 |
| 240 minutes (n=85, n=85, n=85) | 0.7 ± 1.09 | 0.5 ± 1.04 | 0.9 ± 1.29 |
| 255 minutes (n=85, n=85, n=85) | 0.6 ± 1.15 | 0.4 ± 0.86 | 1.0 ± 1.41 |
| 270 minutes (n=85, n=85, n=85) | 0.6 ± 1.13 | 0.5 ± 1.00 | 1.0 ± 1.40 |
| 285 minutes (n=85, n=85, n=85) | 0.8 ± 1.08 | 0.6 ± 1.07 | 1.1 ± 1.42 |
| 300 minutes (n=84, n=85, n=85) | 0.7 ± 1.02 | 0.5 ± 0.95 | 0.9 ± 1.34 |
| 315 minutes (n=84, n=85, n=85) | 0.7 ± 1.10 | 0.4 ± 0.94 | 1.1 ± 1.40 |
| 330 minutes (n=85, n=85, n=85) | 0.7 ± 1.02 | 0.6 ± 1.03 | 1.0 ± 1.38 |
| 345 minutes (n=84, n=85, n=85) | 0.7 ± 1.09 | 0.6 ± 0.99 | 1.0 ± 1.33 |
| 360 minutes (n=85, n=85, n=85) | 0.6 ± 1.12 | 0.6 ± 1.09 | 1.0 ± 1.38 |
The individual symptom score for Water Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes | 2.7 ± 1.12 | 2.8 ± 1.05 | 2.7 ± 1.02 |
| 15 minutes | 2.4 ± 1.17 | 2.6 ± 1.10 | 2.4 ± 1.15 |
| 30 minutes | 2.2 ± 1.23 | 2.3 ± 1.17 | 2.1 ± 1.25 |
| 45 minutes | 1.9 ± 1.22 | 2.0 ± 1.19 | 2.0 ± 1.18 |
| 60 minutes | 1.8 ± 1.21 | 1.9 ± 1.16 | 1.9 ± 1.12 |
| 75 minutes | 1.7 ± 1.21 | 1.8 ± 1.19 | 1.6 ± 1.11 |
| 90 minutes | 1.5 ± 1.29 | 1.6 ± 1.23 | 1.5 ± 1.18 |
| 105 minutes | 1.5 ± 1.22 | 1.6 ± 1.13 | 1.5 ± 1.19 |
| 120 minutes | 1.3 ± 1.15 | 1.3 ± 1.09 | 1.4 ± 1.18 |
| 135 minutes | 1.2 ± 1.11 | 1.3 ± 1.11 | 1.4 ± 1.29 |
| 150 minutes | 1.2 ± 1.12 | 1.2 ± 1.19 | 1.4 ± 1.20 |
| 165 minutes | 1.2 ± 1.14 | 1.2 ± 1.14 | 1.4 ± 1.20 |
| 180 minutes | 1.2 ± 1.07 | 1.1 ± 1.12 | 1.3 ± 1.16 |
| 195 minutes | 1.2 ± 1.15 | 1.2 ± 1.19 | 1.5 ± 1.21 |
| 210 minutes | 1.2 ± 1.14 | 1.1 ± 1.13 | 1.4 ± 1.27 |
| 225 minutes | 1.2 ± 1.13 | 1.1 ± 1.16 | 1.4 ± 1.25 |
| 240 minutes | 1.2 ± 1.16 | 1.1 ± 1.10 | 1.4 ± 1.24 |
| 255 minutes | 1.2 ± 1.12 | 1.1 ± 1.13 | 1.4 ± 1.26 |
| 270 minutes | 1.2 ± 1.13 | 1.1 ± 1.09 | 1.4 ± 1.21 |
| 285 minutes | 1.2 ± 1.08 | 1.2 ± 1.13 | 1.4 ± 1.27 |
| 300 minutes | 1.2 ± 1.02 | 1.1 ± 1.10 | 1.3 ± 1.32 |
| 315 minutes | 1.2 ± 1.09 | 1.2 ± 1.13 | 1.4 ± 1.33 |
| 330 minutes | 1.3 ± 1.14 | 1.2 ± 1.15 | 1.4 ± 1.32 |
| 345 minutes | 1.2 ± 1.15 | 1.2 ± 1.19 | 1.4 ± 1.32 |
| 360 minutes | 1.2 ± 1.20 | 1.3 ± 1.17 | 1.4 ± 1.34 |
The individual symptom score for Itchy Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes (n=85, n=85, n=85) | 3.0 ± 0.93 | 3.2 ± 0.87 | 3.1 ± 1.08 |
| 15 minutes (n=85, n=85, n=84) | 2.6 ± 1.10 | 3.0 ± 1.02 | 2.8 ± 1.15 |
| 30 minutes (n=85, n=85, n=85) | 2.4 ± 1.12 | 2.7 ± 1.17 | 2.4 ± 1.20 |
| 45 minutes (n=85, n=85, n=85) | 2.2 ± 1.14 | 2.3 ± 1.17 | 2.4 ± 1.24 |
| 60 minutes (n=85, n=85, n=85) | 1.9 ± 1.14 | 2.1 ± 1.14 | 2.2 ± 1.23 |
| 75 minutes (n=85, n=85, n=85) | 1.9 ± 1.14 | 2.0 ± 1.20 | 1.9 ± 1.25 |
| 90 minutes (n=85, n=85, n=85) | 1.8 ± 1.21 | 1.8 ± 1.17 | 1.9 ± 1.28 |
| 105 minutes (n=85, n=85, n=85) | 1.8 ± 1.18 | 1.8 ± 1.15 | 1.8 ± 1.29 |
| 120 minutes (n=85, n=85, n=85) | 1.6 ± 1.19 | 1.6 ± 1.14 | 1.7 ± 1.30 |
| 135 minutes (n=85, n=85, n=85) | 1.5 ± 1.14 | 1.5 ± 1.13 | 1.7 ± 1.28 |
| 150 minutes (n=85, n=85, n=85) | 1.5 ± 1.06 | 1.4 ± 1.20 | 1.6 ± 1.32 |
| 165 minutes (n=85, n=85, n=85) | 1.5 ± 1.11 | 1.4 ± 1.24 | 1.7 ± 1.28 |
| 180 minutes (n=85, n=85, n=85) | 1.4 ± 1.11 | 1.4 ± 1.18 | 1.7 ± 1.23 |
| 195 minutes (n=85, n=85, n=85) | 1.5 ± 1.15 | 1.4 ± 1.19 | 1.8 ± 1.30 |
| 210 minutes (n=85, n=85, n=85) | 1.4 ± 1.12 | 1.4 ± 1.21 | 1.7 ± 1.26 |
| 225 minutes (n=85, n=85, n=85) | 1.5 ± 1.15 | 1.4 ± 1.19 | 1.7 ± 1.28 |
| 240 minutes (n=84, n=85, n=85) | 1.6 ± 1.19 | 1.4 ± 1.11 | 1.7 ± 1.29 |
| 255 minutes (n=85, n=85, n=85) | 1.4 ± 1.13 | 1.4 ± 1.18 | 1.6 ± 1.31 |
| 270 minutes (n=85, n=85, n=85) | 1.4 ± 1.09 | 1.4 ± 1.15 | 1.6 ± 1.30 |
| 285 minutes (n=85, n=85, n=85) | 1.3 ± 1.16 | 1.4 ± 1.17 | 1.7 ± 1.42 |
| 300 minutes (n=85, n=85, n=85) | 1.4 ± 1.19 | 1.4 ± 1.18 | 1.7 ± 1.33 |
| 315 minutes (n=85, n=85, n=85) | 1.4 ± 1.19 | 1.4 ± 1.24 | 1.7 ± 1.36 |
| 330 minutes (n=85, n=85, n=85) | 1.5 ± 1.21 | 1.4 ± 1.24 | 1.6 ± 1.38 |
| 345 minutes (n=85, n=85, n=85) | 1.4 ± 1.23 | 1.4 ± 1.27 | 1.8 ± 1.38 |
| 360 minutes (n=85, n=85, n=85) | 1.5 ± 1.34 | 1.4 ± 1.25 | 1.7 ± 1.37 |
The individual symptom score for Nasal Congestion was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes (n=85, n=85, n=85) | 3.4 ± 0.81 | 3.2 ± 0.88 | 3.4 ± 0.76 |
| 15 minutes (n=85, n=85, n=85) | 2.5 ± 1.20 | 2.2 ± 1.25 | 2.7 ± 1.19 |
| 30 minutes (n=85, n=85, n=85) | 1.6 ± 1.33 | 1.5 ± 1.19 | 2.0 ± 1.26 |
| 45 minutes (n=85, n=85, n=85) | 2.5 ± 1.16 | 2.1 ± 1.21 | 2.6 ± 1.22 |
| 60 minutes (n=85, n=85, n=85) | 1.6 ± 1.29 | 1.4 ± 1.20 | 1.8 ± 1.34 |
| 75 minutes (n=85, n=85, n=85) | 2.4 ± 1.25 | 2.1 ± 1.21 | 2.6 ± 1.24 |
| 90 minutes (n=85, n=85, n=85) | 1.6 ± 1.27 | 1.3 ± 1.19 | 1.8 ± 1.34 |
| 105 minutes (n=85, n=85, n=85) | 2.4 ± 1.24 | 2.1 ± 1.20 | 2.6 ± 1.24 |
| 120 minutes (n=85, n=85, n=85) | 1.5 ± 1.26 | 1.4 ± 1.17 | 1.8 ± 1.31 |
| 135 minutes (n=85, n=85, n=85) | 2.4 ± 1.24 | 2.1 ± 1.19 | 2.6 ± 1.26 |
| 150 minutes (n=85, n=85, n=85) | 1.5 ± 1.31 | 1.3 ± 1.19 | 1.8 ± 1.31 |
| 165 minutes (n=85, n=85, n=85) | 2.4 ± 1.26 | 2.0 ± 1.14 | 2.5 ± 1.33 |
| 180 minutes (n=85, n=85, n=85) | 1.4 ± 1.22 | 1.3 ± 1.22 | 1.8 ± 1.39 |
| 195 minutes (n=85, n=85, n=85) | 2.5 ± 1.21 | 2.0 ± 1.15 | 2.6 ± 1.25 |
| 210 minutes (n=85, n=85, n=85) | 1.5 ± 1.31 | 1.3 ± 1.20 | 1.8 ± 1.34 |
| 225 minutes (n=85, n=85, n=85) | 2.4 ± 1.21 | 2.0 ± 1.24 | 2.6 ± 1.28 |
| 240 minutes (n=85, n=85, n=85) | 1.5 ± 1.29 | 1.4 ± 1.21 | 1.8 ± 1.32 |
| 255 minutes (n=85, n=85, n=84) | 2.4 ± 1.26 | 2.0 ± 1.19 | 2.6 ± 1.30 |
| 270 minutes (n=85, n=85, n=84) | 1.6 ± 1.29 | 1.3 ± 1.22 | 1.8 ± 1.46 |
| 285 minutes (n=85, n=85, n=85) | 2.4 ± 1.31 | 2.1 ± 1.19 | 2.6 ± 1.34 |
| 300 minutes (n=85, n=85, n=85) | 1.5 ± 1.31 | 1.3 ± 1.25 | 1.8 ± 1.43 |
| 315 minutes (n=85, n=85, n=85) | 2.4 ± 1.29 | 2.1 ± 1.19 | 2.5 ± 1.39 |
| 330 minutes (n=85, n=85, n=85) | 1.5 ± 1.31 | 1.3 ± 1.24 | 1.8 ± 1.47 |
| 345 minutes (n=85, n=85, n=85) | 2.4 ± 1.28 | 2.0 ± 1.24 | 2.5 ± 1.33 |
| 360 minutes (n=85, n=85, n=85) | 1.5 ± 1.31 | 1.4 ± 1.31 | 1.9 ± 1.51 |
The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.
| units on a scale | Loratadine | Fexofenadine | Placebo |
|---|---|---|---|
| 0 minutes (n=85, n=85, n=85) | 3.0 ± 1.08 | 3.0 ± 1.05 | 2.9 ± 1.17 |
| 15 minutes (n=85, n=85, n=85) | 3.2 ± 1.05 | 3.0 ± 1.06 | 3.0 ± 1.09 |
| 30 minutes (n=85, n=85, n=85) | 2.6 ± 1.19 | 2.8 ± 1.17 | 2.6 ± 1.27 |
| 45 minutes (n=85, n=85, n=85) | 3.0 ± 1.11 | 2.8 ± 1.09 | 2.8 ± 1.06 |
| 60 minutes (n=85, n=85, n=85) | 2.3 ± 1.29 | 2.6 ± 1.27 | 2.4 ± 1.25 |
| 75 minutes (n=85, n=85, n=85) | 2.8 ± 1.16 | 2.6 ± 1.16 | 2.8 ± 1.12 |
| 90 minutes (n=85, n=85, n=85) | 2.0 ± 1.22 | 2.3 ± 1.16 | 2.3 ± 1.25 |
| 105 minutes (n=85, n=85, n=85) | 2.7 ± 1.19 | 2.4 ± 1.17 | 2.6 ± 1.14 |
| 120 minutes (n=85, n=85, n=85) | 1.9 ± 1.24 | 2.0 ± 1.15 | 2.1 ± 1.31 |
| 135 minutes (n=85, n=85, n=85) | 2.6 ± 1.20 | 2.3 ± 1.24 | 2.5 ± 1.24 |
| 150 minutes (n=85, n=85, n=85) | 1.8 ± 1.21 | 1.8 ± 1.17 | 1.9 ± 1.32 |
| 165 minutes (n=85, n=85, n=85) | 2.5 ± 1.17 | 2.2 ± 1.21 | 2.4 ± 1.29 |
| 180 minutes (n=85, n=85, n=85) | 1.7 ± 1.20 | 1.7 ± 1.21 | 1.8 ± 1.29 |
| 195 minutes (n=85, n=85, n=85) | 2.4 ± 1.25 | 2.1 ± 1.17 | 2.4 ± 1.26 |
| 210 minutes (n=85, n=85, n=85) | 1.6 ± 1.21 | 1.7 ± 1.12 | 1.9 ± 1.28 |
| 225 minutes (n=85, n=85, n=85) | 2.3 ± 1.13 | 2.0 ± 1.20 | 2.3 ± 1.25 |
| 240 minutes (n=85, n=85, n=85) | 1.5 ± 1.18 | 1.5 ± 1.15 | 1.7 ± 1.31 |
| 255 minutes (n=85, n=85, n=84) | 2.3 ± 1.19 | 2.0 ± 1.22 | 2.4 ± 1.28 |
| 270 minutes (n=85, n=85, n=85) | 1.5 ± 1.20 | 1.6 ± 1.16 | 1.7 ± 1.29 |
| 285 minutes (n=85, n=85, n=85) | 2.4 ± 1.16 | 2.0 ± 1.26 | 2.4 ± 1.31 |
| 300 minutes (n=85, n=85, n=85) | 1.5 ± 1.14 | 1.4 ± 1.21 | 1.8 ± 1.32 |
| 315 minutes (n=85, n=85, n=85) | 2.4 ± 1.18 | 2.0 ± 1.23 | 2.4 ± 1.30 |
| 330 minutes (n=85, n=85, n=85) | 1.4 ± 1.19 | 1.4 ± 1.22 | 1.7 ± 1.23 |
| 345 minutes (n=85, n=85, n=85) | 2.3 ± 1.20 | 2.0 ± 1.25 | 2.5 ± 1.29 |
| 360 minutes (n=85, n=85, n=85) | 1.4 ± 1.17 | 1.3 ± 1.21 | 1.7 ± 1.27 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Loratadine | — | 0/85 (0%) | 0/85 (0%) |
| Fexofenadine | — | 0/85 (0%) | 0/85 (0%) |
| Placebo | — | 0/85 (0%) | 0/85 (0%) |
| Age, Continuous(years) | Loratadine | Fexofenadine | Placebo | Total |
|---|---|---|---|---|
| Mean | 41.5 ± 13.52 | 43.1 ± 12.21 | 40.6 ± 12.56 | 41.7 ± 12.77 |
| Sex: Female, Male(Participants) | Loratadine | Fexofenadine | Placebo | Total |
|---|---|---|---|---|
| Female | 51 | 53 | 53 | 157 |
| Male | 34 | 32 | 32 | 98 |
No study locations are listed for this record.
The record gives a start of Oct 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Loratadine · Fexofenadine